| What are the main application markets for PressureDOT? |
| The initial focus is on intensive care (ICU) and postoperative monitoring, with future expansion into outpatient applications like metabolic, gastrointestinal, and remote healthcare (e-Health) applications. As digital health and smart sensing adoption grow, continuous internal monitoring presents a strong long-term market opportunity. |
| What is the global market outlook for this technology? |
| The global market for intra-abdominal and gastrointestinal monitoring devices is valued at about $10 billion, with an expected compound annual growth rate (CAGR) of 12–15% over the next five years, driven by rising critical care needs, device miniaturization, and remote monitoring adoption. |
| What is Dotspace’s long-term vision? |
| Built around PressureDOT, Dotspace aims to develop a digital in-body sensing ecosystem—platform for real-world data (RWD). Future products will integrate multi-parameter sensing—such as pH and biomarkers—enhanced by AI analytics, enabling a shift from simple monitoring to intelligent diagnosis. |
| Is Dotspace’s technology protected by patents? |
| Yes. Dotspace holds multiple patent filings in Taiwan, the U.S., China, and the EU, covering wireless transmission, micro-packaging, and multi-sensor technologies, securing strong global IP protection. |
| What is Dotspace’s current fundraising and partnership status? |
| Dotspace is currently raising a $6M Pre-A round to support clinical trials, regulatory submissions, and marketing. The company has established partnerships with leading hospitals and research institutes to advance its clinical validation and market entry. |
